180 related articles for article (PubMed ID: 29738081)
1. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
2. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
[TBL] [Abstract][Full Text] [Related]
3. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
5. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
[TBL] [Abstract][Full Text] [Related]
7. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.
Schmied S; Gostick E; Price DA; Abken H; Assenmacher M; Richter A
Immunology; 2015 Aug; 145(4):558-69. PubMed ID: 25882672
[TBL] [Abstract][Full Text] [Related]
10. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
[TBL] [Abstract][Full Text] [Related]
11. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
[TBL] [Abstract][Full Text] [Related]
12. Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
Koukoulias K; Papadopoulou A; Kouimtzidis A; Papayanni PG; Papaloizou A; Sotiropoulos D; Yiangou M; Costeas P; Anagnostopoulos A; Yannaki E; Kaloyannidis P
Br J Haematol; 2021 Jul; 194(1):158-167. PubMed ID: 34036576
[TBL] [Abstract][Full Text] [Related]
13. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867
[TBL] [Abstract][Full Text] [Related]
15. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
[TBL] [Abstract][Full Text] [Related]
16. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
17. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
18. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
[TBL] [Abstract][Full Text] [Related]
19. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]